Literature DB >> 32169954

Absence of MHC class II on cDC1 dendritic cells triggers fatal autoimmunity to a cross-presented self-antigen.

Christian Wohn1, Valentin Le Guen1, Odessa Voluzan1, Frédéric Fiore2, Sandrine Henri3, Bernard Malissen3,2.   

Abstract

Conventional dendritic cells expressing the XCR1 chemokine receptor (cDC1s) excel at cross-presentation. Here, we developed and used a mouse model in which a Cre recombinase is expressed under the control of the Xcr1 gene while preserving XCR1 expression. We used it to generate mice with conditional deletion of MHC class II (MHCII) molecules on cDC1s. By preventing cDC1s to receive suppressive regulatory T cell inputs via MHCII-restricted interactions, the objective of the present study was to gauge whether MHCII-deficient cDC1s lose their capacity of tolerizing autoreactive CD8+ T cells. Whereas MHCII+ cDC1 readily cross-tolerized strongly autoreactive CD8+ T cells specific for a keratinocyte-derived self-antigen, MHCII-deficient cDC1s converted them into potent effectors capable of triggering a fast-onset lethal autoimmunity associated with severe skin histopathological manifestations. Preventing egress of such pathogenic self-reactive CD8+ T cell effectors from the cutaneous draining lymph nodes abrogated the autoimmune condition. Therefore, our results revealed that the cross-tolerizing capacity of cDC1s is not a property fully acquired at the time they undergo homeostatic maturation but needs to be enforced via MHCII-restricted, suppressive interactions with regulatory T cells.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32169954     DOI: 10.1126/sciimmunol.aba1896

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  10 in total

1.  αvβ8 integrin-expression by BATF3-dependent dendritic cells facilitates early IgA responses to Rotavirus.

Authors:  J Nakawesi; S This; J Hütter; M Boucard-Jourdin; V Barateau; K Getachew Muleta; L J Gooday; K Fog Thomsen; A Garcias López; I Ulmert; D Poncet; B Malissen; H Greenberg; O Thaunat; T Defrance; H Paidassi; K Lahl
Journal:  Mucosal Immunol       Date:  2020-03-11       Impact factor: 7.313

2.  Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication.

Authors:  Marco Gargaro; Giulia Scalisi; Giorgia Manni; Carlos G Briseño; Prachi Bagadia; Vivek Durai; Derek J Theisen; Sunkyung Kim; Marilena Castelli; Chenling A Xu; Gerd Meyer Zu Hörste; Giuseppe Servillo; Maria A Della Fazia; Giulia Mencarelli; Doriana Ricciuti; Eleonora Padiglioni; Nicola Giacchè; Carolina Colliva; Roberto Pellicciari; Mario Calvitti; Teresa Zelante; Dietmar Fuchs; Ciriana Orabona; Louis Boon; Alban Bessede; Marco Colonna; Paolo Puccetti; Theresa L Murphy; Kenneth M Murphy; Francesca Fallarino
Journal:  Immunity       Date:  2022-06-14       Impact factor: 43.474

3.  scRNA-seq generates a molecular map of emerging cell subtypes after sciatic nerve injury in rats.

Authors:  Ditte Lovatt; Alex Tamburino; Alicja Krasowska-Zoladek; Raul Sanoja; Lixia Li; Vanessa Peterson; Xiaohai Wang; Jason Uslaner
Journal:  Commun Biol       Date:  2022-10-19

Review 4.  Conventional Type 1 Dendritic Cells in Intestinal Immune Homeostasis.

Authors:  Izumi Sasaki; Takashi Kato; Hiroaki Hemmi; Yuri Fukuda-Ohta; Naoko Wakaki-Nishiyama; Asumi Yamamoto; Tsuneyasu Kaisho
Journal:  Front Immunol       Date:  2022-05-27       Impact factor: 8.786

5.  XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis.

Authors:  Assaf Weiner; Ziv Ben-Ari; Mathias Heikenwälder; Eran Elinav; Ido Amit; Aleksandra Deczkowska; Eyal David; Pierluigi Ramadori; Dominik Pfister; Michal Safran; Baoguo Li; Amir Giladi; Diego Adhemar Jaitin; Oren Barboy; Merav Cohen; Ido Yofe; Chamutal Gur; Shir Shlomi-Loubaton; Sandrine Henri; Yousuf Suhail; Mengjie Qiu; Shing Kam; Hila Hermon; Eylon Lahat; Gil Ben Yakov; Oranit Cohen-Ezra; Yana Davidov; Mariya Likhter; David Goitein; Susanne Roth; Achim Weber; Bernard Malissen
Journal:  Nat Med       Date:  2021-05-20       Impact factor: 53.440

Review 6.  Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy.

Authors:  Simone Nüssing; Joseph A Trapani; Ian A Parish
Journal:  Front Immunol       Date:  2020-09-23       Impact factor: 7.561

7.  Engineering immunoproteasome-expressing mesenchymal stromal cells: A potent cellular vaccine for lymphoma and melanoma in mice.

Authors:  Jamilah Abusarah; Fatemeh Khodayarian; Nehme El-Hachem; Natasha Salame; Martin Olivier; Mohammad Balood; Katiane Roversi; Sebastien Talbot; Jean-Pierre Bikorimana; Jingkui Chen; Mario Jolicoeur; Louis-Eric Trudeau; Samaneh Kamyabiazar; Borhane Annabi; Francis Robert; Jerry Pelletier; Abed-El-Hakim El-Kadiry; Riam Shammaa; Moutih Rafei
Journal:  Cell Rep Med       Date:  2021-12-21

8.  Rotavirus-Induced Expansion of Antigen-Specific CD8 T Cells Does Not Require Signaling via TLR3, MyD88 or the Type I Interferon Receptor.

Authors:  Konjit Getachew Muleta; Isabel Ulmert; Kedir Hussen Hamza; Sharné van Dijl; Joy Nakawesi; Katharina Lahl
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

9.  Type I Interferons Promote Germinal Centers Through B Cell Intrinsic Signaling and Dendritic Cell Dependent Th1 and Tfh Cell Lineages.

Authors:  Madelene W Dahlgren; Adam W Plumb; Kristoffer Niss; Katharina Lahl; Søren Brunak; Bengt Johansson-Lindbom
Journal:  Front Immunol       Date:  2022-07-13       Impact factor: 8.786

10.  Type II alveolar cell MHCII improves respiratory viral disease outcomes while exhibiting limited antigen presentation.

Authors:  Sushila A Toulmin; Chaitali Bhadiadra; Andrew J Paris; Jeffrey H Lin; Jeremy Katzen; Maria C Basil; Edward E Morrisey; G Scott Worthen; Laurence C Eisenlohr
Journal:  Nat Commun       Date:  2021-06-28       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.